WARNING: These are scams. They are Emails sent to a honeytrap address only ever used for this purpose. Do not reply to these people, they will try to con you into paying out money in return for nothing.
CAVEAT: Please note that some of these Emails may be impersonating a genuine company or person. We wish to make it clear that any such name mentioned within these Emails has no connection to the scam. For the sake of searching, we leave these messages untouched, but we will respond to any concerns left in our comments.
From: Chicago Research Center <[email protected]>
Reply: [email protected]
Date: Fri, 13 Aug 2021 07:56:27 -0700 (PDT)
Subject: ADV: Free Depression Resources for You and Your Loved Ones
From: CHICAGO RESEARCH CENTER
<Suspicious hyperlink>
To: [email protected]
To ensure that you continue receiving our emails,
please add us to your address book or safe-sender list.
[editor_icon_facebook]
<Link to Facebook page>
[editor_icon_instagram]
<Suspicious hyperlink>
[editor_icon_linkdin]
<Hyperlink to a LinkedIn account>
[editor_icon_twitter] <Suspicious hyperlink>
WHO WE ARE:
Established in 2005, Chicago Research Center is a trusted independent
clinical research site dedicated to the advancement of medicine and
treatments. We specialize in phase I-IV clinical trials for the
pharmaceutical and biotechnology industries in sleep, general
medicine, pain, memory, and mood disorders. CRC is proud to have
contributed to the approval by the Federal Drug Administration (FDA)
of more than 30 medications.
OUR
STORY
SOME OF OUR EXCITING NEW STUDIES INCLUDE:
KETAMINE TREATMENT
Esketmaine is a rapid acting FDA-approved antidepressant that is dosed
on a weekly basis via nasal spray. Unlike any other antidepressant on
the market, this medication has been found to increase neural
plasticity, which aids in longer-lasting antidepressant effects.
Designed specifically for treatment-resistant depression.
NOVEL ANTIDEPRESSANT
Zuranolone is a short-term, _as-needed_ antidepressant medication. It
was initially designed for postpartum depression, and has subsequently
been investigated for treatment of insomnia and major depressive
disorder. Zuranolone is only taken for a period of 2-weeks at a time,
with antidepressant effects typically becoming noticable within the
first week.
DIGITAL STUDY
This study is looking at the use of a new smartphone app, designed to
help guide participants through cognitive behavioral therapy (CBT),
and cognitive training. Completely remote study that can be done from
the comfort of your own home!
_AND MANY MORE! CHECK OUT OUR WEBSITE
<Suspicious hyperlink> FOR A FULL
LIST OF ACTIVE CLINICAL TRIALS._
PARTICIPATE
Qualified and enrolled participants may be compensated up to $2,250
for time and travel. Free transportation assistance is often made
available for
in-person studies.
Testimonials
<Suspicious hyperlink> |
Current Studies
<Suspicious hyperlink> |
How It Works <Suspicious hyperlink>
| Apply to Participate
<Suspicious hyperlink>
© Copyright 2021.
Chicago Research Center, Inc.
3401 N. Central Ave.
Chicago, IL 60634
(773)282-9845
To view our privacy policy, click here
<Suspicious hyperlink> .
This message was sent by Chicago Research Center
<Suspicious hyperlink> ,
3401 N. Central Ave. , Chicago, IL, 60634, USA
To contact the sender, reply to this email.
This message may be a newsletter, solicitation or advertisement. Your
request to unsubscribe or block will be enforced immediately.
Change Profile
<Suspicious hyperlink>
| Unsubscribe
<Suspicious hyperlink>
| Block Sender
<Suspicious hyperlink>
| Report Abuse
<Suspicious hyperlink>
| Privacy Policy
<Suspicious hyperlink>
[Online Multi-Channel Marketing and Messaging Software]
<Suspicious hyperlink>